AAAAAA

   
Results: 1-10 |
Results: 10
Germ cell tumor associated primitive neuroectodermal tumors
Authors: Ganjoo, KN Foster, RS Michael, H Donohue, JP Einhorn, LH
Citation: Kn. Ganjoo et al., Germ cell tumor associated primitive neuroectodermal tumors, J UROL, 165(5), 2001, pp. 1514-1516
Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection
Authors: Beck, SDW Foster, RS Bihrle, R Koch, MO Wahle, GR Donohue, JP
Citation: Sdw. Beck et al., Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection, J UROL, 165(5), 2001, pp. 1517-1520
Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer
Authors: Vergouwe, Y Steyerberg, EW Foster, RS Habbema, JDF Donohue, JP
Citation: Y. Vergouwe et al., Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer, J UROL, 165(1), 2001, pp. 84-88
Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer
Authors: Sweeney, CJ Hermans, BP Heilman, DK Foster, RS Donohue, JP Einhorn, LH
Citation: Cj. Sweeney et al., Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer, J CL ONCOL, 18(2), 2000, pp. 358-362
Clinical stage I pure yolk sac tumor of the testis in adults has differentclinical behavior than juvenile yolk sac tumor
Authors: Foster, RS Hermans, B Bihrle, R Donohue, JP
Citation: Rs. Foster et al., Clinical stage I pure yolk sac tumor of the testis in adults has differentclinical behavior than juvenile yolk sac tumor, J UROL, 164(6), 2000, pp. 1943-1944
Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection
Authors: Hermans, BP Sweeney, CJ Foster, RS Einhorn, LE Donohue, JP
Citation: Bp. Hermans et al., Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection, J UROL, 163(6), 2000, pp. 1721-1724
Retroperitoneal lymph node dissection for the management of clinical stageI nonseminoma
Authors: Foster, RS Donohue, JP
Citation: Rs. Foster et Jp. Donohue, Retroperitoneal lymph node dissection for the management of clinical stageI nonseminoma, J UROL, 163(6), 2000, pp. 1788-1792
Retroperitoneal lymph node dissection for the management of clinical stageI nonseminoma - Reply
Authors: Foster, RS Donohue, JP
Citation: Rs. Foster et Jp. Donohue, Retroperitoneal lymph node dissection for the management of clinical stageI nonseminoma - Reply, J UROL, 163(6), 2000, pp. 1792-1792
Cutaneous inflammatory disorder in integrin alpha(E) (CD103)-deficient mice
Authors: Schon, MP Schon, M Warren, HB Donohue, JP Parker, CM
Citation: Mp. Schon et al., Cutaneous inflammatory disorder in integrin alpha(E) (CD103)-deficient mice, J IMMUNOL, 165(11), 2000, pp. 6583-6589
Mucosal T lymphocyte numbers are selectively reduced in integrin alpha(E) (CD103)-deficient mice
Authors: Schon, MP Arya, A Murphy, EA Adams, CM Strauch, UG Agace, WW Marsal, J Donohue, JP Her, H Beier, DR Olson, S Lefrancois, E Brenner, MB Grusby, MJ Parker, CM
Citation: Mp. Schon et al., Mucosal T lymphocyte numbers are selectively reduced in integrin alpha(E) (CD103)-deficient mice, J IMMUNOL, 162(11), 1999, pp. 6641-6649
Risultati: 1-10 |